Remove Peripheral Arterial Disease Remove Pharmacology Remove Risk Factors
article thumbnail

New Guidelines on Peripheral Artery Disease Issued by American Heart Association, American College of Cardiology and Leading Medical Societies

DAIC

A new joint guideline from the American Heart Association (AHA), the American College of Cardiology (ACC) and nine other medical societies reports early diagnosis and treatment of peripheral artery disease is essential to improve outcomes and reduce amputation risk, heart attack, stroke and death for people with Peripheral Artery Disease (PAD).

article thumbnail

A Practical Guide to Understanding and Treating Peripheral Artery Disease

Journal of Cardiovascular Pharmacology

Peripheral arterial disease (PAD) is the third leading cause of atherosclerotic morbidity after coronary heart disease and stroke yet is widely underdiagnosed and undertreated. Treatment of risk factors such as diabetes and cigarette smoking can benefit patients with PAD.

article thumbnail

Post-event follow-up costs in patients with atherosclerotic cardiovascular disease in Spain

Frontiers in Cardiovascular Medicine

Patients with a new or recurrent episode of ASCVD (angina, acute myocardial infarction, transient ischemic attack, stroke, or peripheral arterial disease) between 1-Jan-2017 and 31-Dec-2018 were included. The costs derived from pharmacological treatments were obtained from the NHS pricing nomenclator database ( [link] ).

article thumbnail

Lowering Atherosclerotic Cardiovascular Disease Events by Treating Residual Inflammatory Risk

DAIC

11 Despite the link between inflammation and cardiovascular disease has been proven by extensive research, most physicians have focused on treating high-risk patients with lipid lowering therapies including statin therapy.1,12,13 milligrams per liter (mg/L) are linked to increased risk of heart attacks or risk of a repeat heart attack.23